Background Cancer immunotherapy has changed the standard of care for a subgroup of
patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown …

Conventional anticancer chemotherapy has been historically thought to act through direct
killing of tumor cells. This concept stems from the fact that cytotoxic drugs interfere with DNA …

Conventional chemotherapeutics and targeted antineoplastic agents have been developed
based on the simplistic notion that cancer constitutes a cell-autonomous genetic or …

Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM)
despite the fact that approximately half of treated patients have temozolomide resistance …

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum
based therapy, the standard care for primary ovarian cancer management. A deeper …

It has recently become clear that the tumour microenvironment, and in particular the immune
system, has a crucial role in modulating tumour progression and response to therapy …

Since its inception in 2000, metronomic chemotherapy has undergone major advances as
an antiangiogenic therapy. The discovery of the pro-immune properties of chemotherapy …

Cancer chemotherapy drugs have long been considered immune suppressive. However,
more recent data indicate that some cytotoxic drugs effectively treat cancer in part by …

The antitumor effects of paclitaxel are generally attributed to the suppression of microtubule
dynamics resulting in defects in cell division. New data demonstrated that in ultralow …

Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of
cancer treatment for more than half a century. In some chemosensitive diseases such as …